UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE PATENT TRIAL AND APPEAL BOARD

TEVA PHARMACEUTICALS USA, INC.
Petitioner,

v.

CORCEPT THERAPEUTICS, INC.
Patent Owner.

PGR2019-00048
Patent 10,195,214 B2

PETITIONER'S REPLY TO PATENT OWNER'S RESPONSE

Mail Stop "PATENT BOARD"
Patent Trial and Appeal Board
U.S. Patent & Trademark Office
P.O. Box 1450
Alexandria, VA 22313-1450

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

TABLE OF CONTENTS

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

LIST OF EXHIBITS

Teva Exhibit #	*Description*
1001	Belanoff, J.K., "Concomitant Administration Of Glucocorticoid Receptor Modulators And CYP3A Inhibitors," U.S. Patent No. 10,195,214 B2 (filed June 19, 2017; issued February 5, 2019)
1002	Declaration of David J. Greenblatt, M.D.
1003	Curriculum Vitae for David J. Greenblatt. M.D.
1004	Korlym Label (2012)
1005	Lee *et al*., Office of Clinical Pharmacology Review NDA 20687 (Addendum, Korlym™, Mifepristone) (2012)
1006	FDA Approval Letter for Korlym (mifepristone) tablets, NDA 20217, dated February 17, 2012
1007	Tsunoda, S.M., *et al*., "Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: Effect of ketoconazole," *Clin. Pharmacol. Ther.* 66(5): 461–471 **(**1999)
1008	Ullmann, A., *et al*., "Method For Treating Cushing's Syndrome," U.S. Patent Application Publication No. 2010/0261693 A1 (filed October 13, 2008; published October 14, 2010)
1009	Sartor, O. and Cutler, G.B., "Mifepristone: Treatment of Cushing's Syndrome," *Clinical Obstetrics and Gynecology* 39(2): 506–510 (1996)
1010	Pozza, C., *et al*., "Management Strategies for Aggressive Cushing's Syndrome: From Macroadenomas to Ectopics," *J. Oncol.* 109: 1–9 (2012)
1011	Castinetti, F., "Medical Treatment of Cushing's Syndrome: Glucocorticoid Receptor Antagonists and Mifepristone," *Neuroendocrinology* 92(suppl. 1): 125–130 (2010)
1012	Nieman, L.K., "Successful Treatment of Cushing's Syndrome with the Glucocorticoid Antagonist RU 486*," *J. Clin. Endocrinol. Metab.* 61(3): 536–540 (1985)

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

Teva Exhibit #	*Description*
1013	Brogden, R.N., *et al*., " Mifepristone A Review of its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Potential," *Drugs* 45(3): 384–409 (1993)
1014	Molitch. M.E., "Current approaches to the pharmacological management of Cushing's disease," *Mol. Cell. Endocrinol.* 408: 185–189 (2015)
1015	Sitruk-Ware, R. and Spitz, I.M., "Pharmacological properties of mifepristone: toxicology and safety in animal and human studies," *Contraception* 68: 409–420 (2003)
1016	Heikinheimo, O., "Pharmacokinetics of The Antiprogesterone RU 486 in Women During Multiple Dose Administration," *J. Steriod. Biochem.* 32(1A): 21–25 (1989)
1017	Heikinheimo, O., *et al*., "The pharmacokinetics of mifepristone in humans reveal insights into differential mechanisms of antiprogestin action," *Contraception* 68: 421–426 (2003)
1018	Blasey, C.M., *et al*., "Efficacy and Safety of Mifepristone for the Treatment of Psychotic Depression," *J. Clin. Psychopharmacol*. 31:436–440 (2011)
1019	Belanoff, J.K., "Optimizing Mifepristone Levels in Plasma Serum of Patients Suffering from Mental Disorders Treatable with Glucocorticoid Receptor Antagonists," U.S. Patent No. 8,921,348 B2 (filed October 29, 2013; issued December 30, 2014)
1020	Belanoff, J.K., "Optimizing Mifepristone Levels in Plasma Serum of Patients Suffering from Mental Disorders Treatable with Glucocorticod Receptor Antagonists," U.S. Patent No. 8.598,149 B2 (filed August 27, 2008; issued December 3, 2013)
1021	Castinetti, F., *et al*., "Merits and pitfalls of mifepristone in Cushing's syndrome," *Eur. J. Endocrinol.*160: 1003–1010 (2009)
1022	Jang, G.R., *et al*., "Identification of CYP3A4 as the Principal Enzyme Catalyzing Mifepristone (RU 486) Oxidation in Human Liver Microsomes," *Biochem. Pharmacol.* 52: 753–761 (1996)

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

Teva Exhibit #	***Description***
1023	Greenblatt, D., "*In Vitro* Prediction of Clinical Drug Interactions With CYP3A Substrates: We Are Not There Yet," *Clin. Pharm. Ther*. 95(2): 133–135 (2014)
1024	Greenblatt, D.J., *et al*., "Mechanism of cytochrome P450-3A inhibition by ketoconazole," *J. Pharm. Pharmacol.* 63: 214–221 (2011)
1025	Greenblatt, D.J. and von Moltke, L.L., "Clinical Studies of Drug-Drug Interactions: Design and Interpretation," in *Enzyme- and Transporter-Based Drug-Drug Interactions: Progress and Future Challenges*. Pang, K.S. *et al*., ed., pp. 625–649, New York, Springer: (2010)
1026	Greenblatt, D.J., *et al*., "The CYP3 Family" in *Cytochromes P450: Role in the Metabolism and Toxicity of Drugs and other Xenobiotics*. Ionnides, C., ed., pp. 354–383, Royal Society of Chemistry: (2008)
1027	Ohno, Y., *et al*., "General Framework for the Quantitative Prediction of CYP3A4-Mediated Oral Drug Interactions Based on the AUC Increase by Coadministration of Standard Drugs," *Clin. Pharmacokinet.* 46(8): 681–696 (2007)
1028	Archive History of NCT00936741 History of Changes for Study: NCT00936741 An Extension Study of CORLUX in the Treatment of Endogenous Cushing's Syndrome (July 9, 2009) on ClinicalTrials.gov
1029	Fleseriu, M., *et al*., "Mifepristone, a Glucocorticoid Receptor Antagonist, Produces Clinical and Metabolic Benefits in Patients with Cushing's Syndrome," *J. Clin. Endocrinol. Metab.* 97(6):2039–2049 (2012)
1030	Morgan, F.H. and Laufgraben, M.J., "Mifepristone for Management of Cushing's Syndrome," *Pharmacotherapy* 33(3):319–329 (2013)
1031	Schteingart, D.E., "Drugs in the medical treatment of Cushing's syndrome," *Expert Opin. Emerging Drugs* 14(4):661–671 (2009)

DOCKET ALARM
Find authenticated court documents without watermarks at docketalarm.com.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.